Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review

Bindiganavile, Shruthi Harish; Bhat, Nita; Lee, Andrew G.; Gombos, Dan S.; Al‐Zubidi, Nagham

doi:10.36401/jipo-20-21

Cited by 15 publications

(9 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A baseline eye examination before treatment, followed by prompt referral to the ophthalmologist in the event of new complaints of potential symptoms such as red, painful, dry eyes, or visual disturbances, is recommended [10]. The eye may be susceptible to toxicity due to several factors, including its inherently robust blood supply, the presence of subpopulations of rapidly dividing cells, and an abundance and variety of cell surface receptors [11].…”

Section: Discussionmentioning

confidence: 99%

“…The severity of mAb-associated ocular toxicities is also variable, ranging from minor ocular irritation to severe vision-threatening events [11]. Overall, it is difficult to ascertain the incidence of ocular adverse effects in oncology patients, but they have been reported with increased frequency recently [10]. Furthermore, the mechanism of these adverse effects is largely undetermined.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma

Idogun¹,

Kayali²

2022

Cureus

View full text Add to dashboard Cite

Isatuximab is a newly approved targeted therapy for the treatment of patients with advanced multiple myeloma. Infusion reactions happen often with targeted therapies like isatuximab and can be severe or even life-threatening. However, ocular infusion reactions are rare. We report a 75-year-old female who presented with right eye erythema and associated pain and was found to have had a rapid onset of unilateral hemorrhagic chemosis following an initial infusion of isatuximab. She developed erythema in her right eye, associated with pain, swelling, burning, and a foreign body sensation. Visual acuity in the right eye decreased to light perception only within the first few minutes. The infusion was discontinued, and the patient was treated with steroids and intraocular pressure-lowering drugs. She was monitored for 24 hours and then discharged after symptomatic improvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma

Idogun¹,

Kayali²

2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Такая фармакодинамика делает эти препараты более специфичными для раковых клеток, в отличие от лекарственных средств «традиционной» химиотерапии, чьё действие обычно направлено на подавление размножения всех быстро делящихся клеток, что объясняет их высокую цитотоксичность для организма человека [1]. В то время как компоненты ТТ оказывают скорее цитостатический эффект, подавляя рост опухоли [2]. Вот почему данные препараты более эффективны и имеют меньше побочных эффектов, благодаря их высокой специфичности.…”

Section: Introductionunclassified

“…Побочные эффекты таргеных препаратов со стороны органа зрения относят к одним из самых часто встречаемых побочных эффектов ТТ [2], порой они могут быть инвалидизирующими и необратимыми, об этом следует помнить, тщательно собирая анамнез у онкологического больного с жалобами со стороны органа зрения. Среди побочных эффектов ТТ со стороны органа зрения описаны: синдром сухого глаза, конъюнктивиты, кровоизлияния под конъюнктиву, дисфункция мейбомиевых желёз, блефариты, заворот/выворот век, халязионы, cornea verticillata, кератиты (перифозин), эрозии роговицы, увеиты (передний, промежуточный, задний, панувеит), периорбитальный отёк (часто для иматиниба), экзофтальм, отёк слезоотводящих путей (иногда с их обструкцией), оптический неврит (редко), отёк диска зрительного нерва, кровоизлияния в сетчатку, окклюзии центральной артерии или центральной вены сетчатки и их ветвей [2,3].…”

Section: Introductionunclassified

“…Именно на этот путь избирательно действуют ингибиторы МЕK. В настоящее время их в основном используют для лечения пациентов с прогрессирующей меланомой кожи в комбинации с ингибиторами BRAF [2,7]. Однако такая терапия существенно повышает частоту развития побочных эффектов со стороны органа зрения [8].…”

Section: Introductionunclassified

See 1 more Smart Citation

A clinical case of the development of choroidal neovascularization in a patient with skin melanoma on the background of therapy with MEK and BRAF inhibitors

Tkachenko

Belekhova

Zhukova

et al. 2022

Ophthalmology Reports

View full text Add to dashboard Cite

The emergence of targeted therapy has become a significant breakthrough in the management of cancer patients, but even it is not without drawbacks. The article describes a clinical case of the development choroidal neovascularization in a 42-year-old patient with stage IV skin melanoma during 15 months of therapy with MEK and BRAF inhibitors. Clinicians need to remember that such patients may have not only MEK-associated retinopathy, but also other pathological changes in the retina, in particular choroidal neovascularization, which may be associated with both the chemotherapy they receive and the paraneoplastic syndrome itself against the background of the course of the underlying disease. Timely diagnosis and adequate management tactics allow such patients to preserve visual functions.

show abstract

Marine algae‐derived characterized bioactive compounds as therapy for cancer: A review on their classification, mechanism of action, and future perspectives

Liao,

Chen,

Shan

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

In 2022, there were around 20 million new cases and over 9.7 million cancer‐related deaths worldwide. An increasing number of metabolites with anticancer activity in algae had been isolated and identified, which were promising candidates for cancer therapy. Red algae are well‐known for the production of brominated metabolites, including terpenoids and phenols, which have the capacity to induce cell toxicity. Some non‐toxic biological macromolecules, including polysaccharides, are distinct secondary metabolites found in many algae, particularly green algae. They possess anticancer activities by inhibiting tumor angiogenesis, stimulating the immune response, and inducing apoptosis. However, the structure–activity relationship between these components and antitumor activity, as well as certain taxa within the algae, remains relatively unstudied. This work is based on the reports published from 2003 to 2024 in PubMed and ISI Web of Science databases. A comprehensive review of the characterized algal anticancer active compounds, together with their structure and mechanism of action was performed. Also, their structure–activity relationship was preliminarily summarized to better assess their potential properties as a natural, safe bioactive product to be used as an alternative for the treatment of cancers, leading to new opportunities for drug discovery.

show abstract

Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review

Cited by 15 publications

References 108 publications

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma

A clinical case of the development of choroidal neovascularization in a patient with skin melanoma on the background of therapy with MEK and BRAF inhibitors

Marine algae‐derived characterized bioactive compounds as therapy for cancer: A review on their classification, mechanism of action, and future perspectives

Contact Info

Product

Resources

About